Christopher Cannon: Clopidogrel Monotherapy is Superior to Aspirin Monotherapy for MACCE Prevention
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, posted on LinkedIn:
”New meta-analysis: “clopidogrel monotherapy is superior to aspirin monotherapy for MACCE prevention with no increase in the risk of bleeding.” The CAPRIE trial had it right 20 years ago.
I have been shifting more and more of my patients to long-term clopidogrel in place of ASA.”
Read the full article here.
Title: Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis
Authors: Marco Valgimigli, Ki Hong Choi, Daniele Giacoppo, Felice Gragnano, Takeshi Kimura, Hirotoshi Watanabe, Hyo-Soo Kim, Jeehoon Kang, Kyung Woo Park, Alf-Åge Pettersen, Mark Woodward, Deepak L Bhatt, Paolo Calabrò, Dominick J Angiolillo, Roxana Mehran, Young Bin Song, Joo-Yong Hahn
Stay updated with Hemostasis Today.
-
May 23, 2026, 03:55WFH Initiative Brings Hope to the Hemophilia Community in India
-
May 23, 2026, 03:47Satyam Arora: Welcoming the New ISBT Board for the 2026 Term
-
May 23, 2026, 03:33Brig Tathagata Chatterjee: Connecting With World Leaders in Hematology at ISH Congress
-
May 23, 2026, 03:18Mathangi Kumar: Dental Management Strategies for Congenital Hemophilia
-
May 23, 2026, 03:02Maitri Vaishnav: Anatomical Variability and Surgical Relevance of Corona Mortis
-
May 23, 2026, 02:26Muhammad Hashim: When the Blood Smear Told a Different Story Behind a ‘Critical’ Platelet Count
-
May 23, 2026, 02:20Augustina Isioma Ikusemoro: Understanding One of the Most Common and Preventable Transfusion Reactions
-
May 23, 2026, 02:15What’s Your Advice for the Newly Diagnosed? – ITP Support Association
-
May 23, 2026, 02:08Rob Maloney: When You Stop Building Only a Career and Start Building a Life of Significance